Finance

Lists
0460:HKG
Sihuan Pharmaceutical Holdings Group Ltd
HK$0.78
+2.61%
(+0.020) 1D
Sep 4, 4:08:01 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 0460...
Open
HK$0.78
High
HK$0.80
Low
HK$0.78
Mkt. cap
7.16B
Avg. vol.
0.00
Volume
26.07M
Dividend
2.78%
Quarterly dividend
HK$0.01
Ex-dividend date
Jun 30, 2026
P/E ratio
20.15
52-wk high
HK$1.92
52-wk low
HK$0.74
EPS
HK$0.04
Shares outstanding
9.47B
No. of employees
3K
Open
HK$0.78
High
HK$0.80
Low
HK$0.78
Mkt. cap
7.16B
Avg. vol.
0.00
Volume
26.07M
Dividend
2.78%
Quarterly dividend
HK$0.01
Ex-dividend date
Jun 30, 2026
P/E ratio
20.15
52-wk high
HK$1.92
52-wk low
HK$0.74
EPS
HK$0.04
Shares outstanding
9.47B
No. of employees
3K
News stories
From web sources and news partners
Profile
Sihuan Pharmaceutical is a Chinese pharmaceutical manufacturer with headquarters in Beijing and branch office in Haikou, Hainan Province. The main company in the group is the holding company Sihuan Pharmaceutical Holdings Group Ltd, which is listed on the Hong Kong stock market. Sihuan Pharmaceutical is collaborating with the Academy of Military Medical Science in the development of the drug JK-05, intended for the treatment of Ebola virus disease. The company has been challenged by Fujifilm Holdings Corporation, which has stated that JK-05 infringes its patent rights regarding Avigan. Wikipedia
About Sihuan Pharmaceutical Holdings Group Ltd
CEOGuo Weicheng
Employees2.71K
Founded2001
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
735.90M
735.90M
580.61M
580.61M
Cost of goods sold
213.60M
213.60M
239.78M
239.78M
Cost of revenue
213.60M
213.60M
239.78M
239.78M
Research and development expenses
69.21M
69.21M
52.79M
52.79M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
337.39M
337.39M
212.22M
212.22M
Operating expense
386.99M
386.99M
233.15M
233.15M
Total operating expenses
600.59M
600.59M
472.93M
472.93M
Operating income
135.31M
135.31M
107.68M
107.68M
Other non operating income
-
-
-
-
EBT including unusual items
130.12M
130.12M
182.99M
182.99M
EBT excluding unusual items
111.67M
111.67M
99.80M
99.80M
Income tax expense
70.51M
70.51M
76.70M
76.70M
Effective tax rate
54.19%
54.19%
41.92%
41.92%
Other operating expenses
-19.61M
-19.61M
-31.87M
-31.87M
Net income
38.55M
38.55M
112.35M
112.35M
Net profit margin
5.24%
5.24%
19.35%
19.35%
Earnings per share
-
-
-
-
Interest and investment income
24.62M
24.62M
11.03M
11.03M
Interest expense
-48.30M
-48.30M
-34.66M
-34.66M
Net interest expenses
-23.69M
-23.69M
-23.64M
-23.64M
Depreciation and amortization charges
-
-
-
-
EBITDA
169.25M
169.25M
149.15M
149.15M
Gain or loss from assets sale
-2.73M
-2.73M
-
-
AI content may include mistakes. Learn more
Google apps